摘要
^131I治疗DTC已有50余年历史,其可降低疾病的复发率及病死率,目前已成为DTC的主要治疗手段之一。然而大剂量^131I对身体有辐射损伤风险,越来越多的研究集中于^131I治疗后的近期和远期不良反应。尽管尚有许多问题存在争议,但随着临床循证医学证据的增加,人们关于^131I治疗后的不良反应认识逐渐清晰。笔者就目前^131I治疗DTC对患者各系统的不良影响进行综述。大剂量^131I治疗引起的严重不良反应十分罕见,但是对各系统仍存在不同程度损害。临床医师应掌握循证医学证据,采取积极措施使治疗后不良反应发生率及严重程度降到最低。
DTC is considered the most common endocrine neoplasm, and 131I therapy has been proven to be an important component in the management strategy. Currently, most research focuses on the adverse effects of radiation exposure to 131I therapy. Some results, based on large-scale and long-term inves- tigation, show new information. Although 131I therapies are usually well tolerated, clinicians involved in the management of DTC need to be aware of the potential toxicity of 131I and take all measures to reduce these effects to a minimum. The aim of this review is to present the adverse effects of 131I therapy for DTC.
出处
《中华核医学与分子影像杂志》
CSCD
北大核心
2012年第6期474-477,共4页
Chinese Journal of Nuclear Medicine and Molecular Imaging
基金
教育部科学技术研究重点项目(210269)
湖北省教育厅自然科学研究项目(B20101206)